A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer

Inclusion Criteria: * Gastric cancer confirmed by histopathological or cytological diagnosis; * unresectable locally advanced or recurrent/metastatic gastric cancer; * age 18-75 years, regardless of gender; * ECOG score 0-2; * previously received second-line treatment for advanced gastric cancer with disease progression during or after treatment; * at least one measurable lesion present according to RECIST 1.1 criteria; * laboratory tests meeting the following requirements: (1) Blood routine: HGB≥70g/L; WBC≥4.0×10\^9/L; NEUT≥1.5×10\^9/L; PLT≥90×10\^9/L; (2) Blood biochemistry: ALT, AST≤2.5×upper limit of normal (ULN), serum creatinine≤1.5×upper limit of normal; * negative pregnancy test for patients of childbearing potential and voluntary use of effective and reliable contraception during the trial. Exclusion Criteria: * Participation in other anti-tumor drug clinical trials within 4 weeks prior to enrollment; * Any of the following conditions that may interfere with oral medication: inability to swallow, chronic diarrhea, or intestinal obstruction; * Concurrent receipt of any other systemic anti-tumor therapy (excluding local treatment); * Previous treatment with VEGFR inhibitors (excluding ramucirumab; pan-targeted TKIs are excluded); * Known history of allergy to any component of the study drugs; * Subjects with active infectious diseases; * Patients deemed unsuitable for enrollment by the investigator due to potential increased study-related risks or possible interfere…